Background and Purpose-Home-time (HT) is a stroke outcome measure based on time spent at home after stroke. We hypothesized that HT assessment would be feasible and valid using national data. 
R obust measures of stroke functional outcome are required for clinical trials, observational epidemiology, and quality improvement programs. 1 The ideal measure should be relevant to patients/carers, responsive to change and widely available at low cost. In person, detailed assessment may not be possible for large or geographically dispersed populations. In trials, we use modified Rankin Scale (mRS). However, in large studies with limited resource, low response rate risks substantial attrition bias. Thus, we need outcomes which approximate to mRS but which are available without direct follow-up.
Home-time (HT) is a measure of the time spent back at the person's home during a predefined period after a stroke. It accounts for survival, time spent in hospital or rehabilitation settings, readmission, and institutionalization. 2 HT has been shown to be a valid marker of functional outcomes and is valued by people living with stroke. 3 HT is an attractive measure for population studies, but to date validation has been limited to trials, quality improvement, or insurance datasets. 2, 4 We sought to describe the feasibility and prognostic validity of using HT at scale in a national dataset.
Methods

Datasets
The datasets used in this project are managed by Information Services Division, NHS Scotland. Access to these data is made through the Information Request Service.
Stroke data were from the Scottish Stroke Care Audit (SSCA). SSCA has been described previously, 5 in brief, this resource collects patient-level data from all Scottish hospitals providing stroke care. Participation in the SSCA is mandatory as data are used to improve stroke care. We performed individual patient-level linkage of SSCA to national health and social care datasets using Scottish Morbidity Records 6 and Mortality data. These datasets all have robust quality control processes. 6 A unique patient identifier, the Community Health Index, was used to facilitate the linkage. We quantified length of initial stay (even if across hospitals), readmission (and length of subsequent stays), institutionalization and death. Using SSCA data for research has been approved by Scotland A REC: 10/MRE00/76; Privacy Advisory Committee Ref: 76/11.
Analyses
We attempted to describe HT for all strokes contained in SSCA, censoring at the standard time of 90 days. 2 HT follow-up period started on admission date (or onset date for in-hospital cases). HT was the number of full days not in hospital and where discharge destination was same as at admission (including where care-home was the prestroke residence).
To assess feasibility, we described the proportion of stroke events held in SSCA that could have HT calculated. We described prognostic validity by comparing HT to predefined variables known to be associated with outcome: age (years); National Institutes of Health Stroke Scale (NIHSS; baseline and post-thrombolysis); stroke type (ischemic/hemorrhagic), and Six Simple Variables scale (SSV). SSV is a prognostic scale that includes prestroke living arrangements and independence, and poststroke orientation, arm movement, mobility and verbal response. 7 We assessed SSV as an ordinal scale, in aggregate and individual components, and as a quasi-continuous measure including age. 8 SSV is used as a case-mix adjuster in trials and has been shown to have excellent prognostic utility. 7 Age and NIHSS were combined to calculate SPAN score (Stroke Prognostication Using Age and NIHSS) another validated prognostic scale. 9 We described association for the complete group and subgroups of 90-day survivors and those admitted from home. We correlated HT 
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with survival and length of stay. We used Spearman rank correlation with strength of association described using conventional categorizations. 10 Analyses were performed using SPSS software version 21 (IBM Corp, Armonk, NY).
Results
We Figure) . HT was associated with individual SSV factors ( Table 2) 
Discussion
We have demonstrated that in a national dataset of over a hundred thousand stroke admissions, it is feasible to calculate HT using routinely recorded data. HT derived in this way correlates with factors that predict recovery and should be a reasonable proxy of functional outcome.
Although our study was limited to Scotland, our findings will be relevant to any healthcare system that collects stroke and healthcare utilization data. Countries with national stroke registries that lack resource for postdischarge follow-up may be particularly interested in our findings. HT offers an inexpensive, time-efficient method of outcome assessment that can be used for research, audit and service planning. In Scotland we have already started using HT for outcome comparisons across stroke centers (Material I in the online-only Data Supplement).
The strengths of our approach include the size of our dataset, giving unparalleled precision in analyses. Our inclusive sampling frame included all patients with stroke treated in a Scottish hospital and covers all rural and urban settings and socioeconomic strata. Our inclusive approach is reflected in the range of outcomes demonstrated. Previous work has suggested that a mean HT of around 50 days is equivalent to a mRS of 3.
2,4 Thus, our SSCA data suggest a broader range of stroke outcomes than usually seen in a clinical trial. Our findings were robust across a series of subgroups, although correlation with length of stay and mortality shows that HT offers something more than if using these values alone.
There are limitations to our work. Assessments of prognosis were limited to baseline factors only, albeit baseline factors known to have excellent predictive accuracy. We did not have full data for all factors of interest, but this further emphasizes the difficulty of outcome assessment at scale and the potential utility of our HT approach. However, the consistency of association between HT and all prognostic factors is reassuring. We recognize that comparisons with mRS would be a useful assessment of concurrent validity. Such validations, using trial and registry data, have been described and consistently report strong association of HT with mRS. 2, 4, 11 There is no reason to think the relationship would differ in larger scale, real-world data.
Granularity of information at the individual patient level was limited and there are plausible situations where our derived HT may be erroneous. For example, our data capture would miss a person who is a temporary resident or emigrates after stroke. We believe such occurrences are unusual; only 700 (0.7%) SSCA patients did not have a Scottish postcode. Admission to care-home after discharge may also be missed, and methods for capturing care-home admission from routine sources are being developed. 12 We have demonstrated feasibility and validity of 90 day HT for stroke. The approach could be easily applied to other diseases and other time points. Use of HT after subarachnoid hemorrhage is described, 13 but the HT concept could be used beyond cerebrovascular disease allowing a big data approach to other chronic conditions. 14 
